HOME >> BIOLOGY >> NEWS
New monoclonal antibody therapies offer significant survival advantage for breast cancer patients

Paris, France, Monday 31 October 2005 - Results from the first and only interim analysis of an important trial assessing the potential of Herceptin (trastuzumab) to improve disease-free survival (DFS) in HER-2 positive breast cancer patients after adjuvant chemotherapy, have shown that Herceptin affords a significant survival advantage. These new findings were released at the 13th European Cancer Conference (ECCO) on the recommendation of the Independent Data Monitoring Committee.

The study in question, an international, multicentre, randomised, 3-arm trial is being conducted by the Breast International Group (BIG) in collaboration with the pharmaceutical company Roche AG, manufacturers of Herceptin. In total, 5,090 early breast cancer patients have been enrolled into this trial by the 478 participating institutions from Europe, Canada, South Africa, Israel, the Asia Pacific Region, Japan and Latin America. All women accrued had HER-2 positive breast cancer (either node negative or positive) and had completed at least four cycles of an acceptable (neo) adjuvant chemotherapy regimen. For women with hormone receptor positive disease, adjuvant endocrine therapy (most commonly tamoxifen) followed chemotherapy. The average age of study participants is 49 years.

The aim of this trial is to compare the effect of 1 year of Herceptin infusions, given every 3 weeks, with one year of simple observation, on survival primarily DFS but also overall survival (OS), relapse-free survival (RFS) and distant disease free survival (DDFS), as well as comparable assessment of overall and cardiac safety. The study also consists of a 2-year arm where 2 years of 3-weekly Herceptin is being compared with observation.

Results from the 1-year arm of the study, showcased at ECCO 13, show that Herceptin is associated with a significant improvement in DFS in this group of patients. The difference in Herceptin treated women was 85.8% compared to 77.4% of women on observati
'"/>

Contact: Kirsten Mason
kirsten.mason@toniclc.com
44-077-969-55353
Federation of European Cancer Societies
31-Oct-2005


Page: 1 2 3

Related biology news :

1. Report calls for improved monoclonal antibodies against solid tumors
2. First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology
3. New antibody for EGFR causes lung cancer regression
4. A key antibody, IgG, links cells capture and disposal of germs
5. Research pinpoints West Nile virus antibody binding site
6. A single sugar found responsible for an antibodys ability to treat inflammation
7. Study shows how protein raises antibody output
8. Researchers link specific antibody presence to prevention of mother-to-baby HIV transmission
9. New study shows antibody-interleukin complexes stimulate immune responses
10. High resolution snapshots detail dynamics of a cocaine antibody
11. Immune substances may help antibody-based drugs fight cancer

Post Your Comments:
(Date:11/4/2014)... School of Medicine announced today that it is ... by the Bill & Melinda Gates Foundation. ... and Reproductive Sciences; and Vice Chair of Research ... Medicine will pursue an innovative global health and ... Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds ...
(Date:11/4/2014)... VILNIUS, Lithuania , Nov. 4, 2014 /PRNewswire/ ... identification technologies, today announced that the latest version ... place in the Ongoing MINEX evaluation ... interoperability of fingerprint algorithms using the INCITS 378 ... a mandatory requirement in public tenders in ...
(Date:11/2/2014)... , James Dacey explores the ways in which physicists ... innovations from the lab into the commercial market. , ... companies as they move from prototype to product is ... physics-based inventions are usually far from market-ready when initially ... lot more complicated than had been originally thought. , ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3The 'valley of death' facing physics start-ups 2
(Date:11/26/2014)... Texas (PRWEB) November 26, 2014 ... Industry is an in-depth research report on the ... the report introduces Palmitic Acid, basic information, including ... policy analysis, and news analysis, etc. , ... analyzes Palmitic Acid market in China ...
(Date:11/26/2014)... TOKYO , 25 novembre 2014 /PRNewswrie/ -- Theravalues ... per il mercato europeo in occasione di Hi Europe ... ). Si tratta della curcumina con ... tecnologia amorfa (senza cristalli) e ingredienti approvati dalle norme ... presente nella spezia della pianta curcumina ( Curcuma longa ...
(Date:11/24/2014)... , UAE, November 24, 2014 ... "Sheikh Hamdan Bin Rashid Al Maktoum Awards for Medical ... Dubai, United Arab Emirates , on ... ) , The Carter Center which ... Services is actively involved in numerous programs that aim ...
(Date:11/24/2014)...   First published ... Elsevier , a world-leading provider of scientific, technical ... the launch of the latest title in the Current ... Food Science . Current ... new platform to keep up-to-date with the expanding volume of ...
Breaking Biology Technology:Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3Five US Winners Among Recipients of Hamdan Medical Awards 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
Cached News: